ArticleBMC surgery2025
Improving the efficacy of functional endoscopic sinus surgery in chronic rhinosinusitis with nasal polyps through the combination of budesonide infiltration therapy.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is a refractory inflammatory disorder often necessitating functional endoscopic sinus surgery (FESS) after inadequate response to medical therapy. This study aimed to evaluate the clinical efficacy and safety of combining FESS with intraoperative budesonide infiltration therapy in patients with CRSwNP.
methodsA retrospective study was conducted from January 2022 to June 2024, including 209 CRSwNP patients. The observation group (n = 91) received FESS with intraoperative budesonide infiltration, while the control group (n = 118) underwent FESS alone. Clinical efficacy, olfactory function, mucociliary clearance, nasal ventilation function, complication rates, and recurrence were assessed. Data were analyzed using independent t-tests for continuous variables and Chi-square tests for categorical variables, with statistical significance set at p < 0.05.
resultsThe observation group demonstrated significantly higher clinical efficacy, with a total effective rate of 87.91% compared to 66.95% in the control group (p < 0.001). Improvements were observed in olfactory function (1.08 ± 0.05 vs. 2.36 ± 0.18, p < 0.001), ciliary clearance rate (72.32 ± 6.05% vs. 66.24 ± 6.47%, p < 0.001), and ciliary clearance speed (5.51 ± 0.73 mm/min vs. 4.01 ± 0.73 mm/min, p < 0.001). Additionally, the incidence of complications was significantly lower in the observation group (4.40% vs. 12.71%, p = 0.04). No systemic corticosteroid-related adverse effects were observed.
conclusionsFESS combined with intraoperative budesonide infiltration therapy might improve olfactory recovery, nasal function, and overall clinical efficacy, while potentially reducing postoperative complications in CRSwNP patients, suggesting it could be a safe and effective adjunctive intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.